ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 7, 2020

9:00AM-11:00AM: Abstract Number: 0822

Effectiveness After Transition to SB4 (Brenzys, Etanercept Biosimilar) versus Continuation of Etanercept (ETN) Originator (Enbrel) Among Rheumatoid Arthritis (RA) Patients in Low Disease Activity: A Prospective Multinational Multicenter Observational Study

RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

9:00AM-11:00AM: Abstract Number: 0912

Effectiveness of DETECT Algorithm in Japanese Systemic Sclerosis Patients with Old or New Hemodynamic Definition of Pulmonary Arterial Hypertension

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 0799

Effectiveness of Electronic Drug Monitoring Feedback in Order to Increase Adherence in RA Patients Starting with a Biological DMARD

RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

9:00AM-11:00AM: Abstract Number: 0621

Effectiveness of Screening in Patients with Rheumatic Disease Before Commencing Biologic Therapy and Risk of Active Tuberculosis

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0895

Effects of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19-Subunit of Interleukin-23, on Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Pooled Results Through Week 24 from Two Phase 3 Studies

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0573

Effects of Successive Switches of Two Different Biosimilars of Etanercept on Outcomes in Inflammatory Rheumatic Diseases in Daily Practice

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0865

Efficacy and Safety of Evobrutinib (M2951) in Adult Patients with Systemic Lupus Erythematosus Who Received Standard of Care Therapy: A Phase II, Randomized, Double-blind, Placebo-controlled Dose Ranging Study

SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0894

Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0882

Efficacy and Safety of Secukinumab in Patients with Spondyloarthritis and Enthesitis at the Achilles Tendon: 52-weeks Results from a Randomized, Placebo-controlled Phase 3b Trial

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0818

Efficacy and Safety of Switching Jakinibs in Rheumatoid Arthritis

RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

9:00AM-11:00AM: Abstract Number: 0889

Efficacy of Secukinumab Treatment in Patients with Early Psoriatic Arthritis: A Pooled Analysis of 4 Phase 3 Studies

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0679

Epidemiology of Intra-Articular Mineralization on Knee Dual-Energy Computed Tomography: The Multicenter Osteoarthritis Study

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0525

Epidemiology of Thromboembolic Complications Among Hospitalized Patients with Antiphospholipid Syndrome in the United States

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 0782

Epigenetic Regulation of Metabolic Transporters in Rheumatoid Arthritis Fibroblast-Like Synoviocytes

RA – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0722

Evaluation of Flare Rate and Tapering Strategies in Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical Poster II: JIA

«Previous Page
1
…
7
8
9
10
11
…
32
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].